Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Exelixis |
---|---|
Information provided by: | Exelixis |
ClinicalTrials.gov Identifier: | NCT00312780 |
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL784 when given daily to patients with albuminuria due to diabetic nephropathy. XL784 is a small molecule reno-protective metalloproteinase inhibitor, inhibiting both ADAMs (including ADAM10, a target of significant interest because of its important role in blood vessel formation and cell proliferation, and ADAM17/TACE, activation of which has been associated with renal deterioration) and MMPs (including MMP-2 and MMP-9). XL784 was specifically optimized to be MMP-1 sparing, which may be clinically significant because inhibition of MMP-1 has been hypothesized to be associated with musculoskeletal toxicity.
Condition | Intervention | Phase |
---|---|---|
Albuminuria Diabetic Nephropathy |
Drug: XL784 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | XL784-201 |
Study First Received: | April 7, 2006 |
Last Updated: | January 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00312780 |
Health Authority: | United States: Food and Drug Administration |
albuminuria diabetic nephropathy diabetes |
Signs and Symptoms Proteinuria Albuminuria Diabetic Nephropathies Urologic Diseases Urination Disorders |
Diabetes Mellitus Endocrine System Diseases Endocrinopathy Kidney Diseases Diabetes Complications |
Urological Manifestations |